Get the Stockscreener App
6.62
1.22%
0.08
Pre-market:
6.57
-0.05
-0.76%
Immunitybio Inc stock is traded at $6.62, with a volume of 13.38M.
It is up +1.22% in the last 24 hours and up +155.60% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$6.54
Open:
$6.53
24h Volume:
13.38M
Relative Volume:
0.53
Market Cap:
$6.52B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-6.8247
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+17.38%
1M Performance:
+155.60%
6M Performance:
+168.02%
1Y Performance:
+104.32%
1-Day Range:
$6.40
$6.87
1-Week Range:
$5.6101
$7.1366
52-Week Range:
$1.83
$8.28
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
6.62 | 6.44B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio (NASDAQ:IBRX) Stock Price Up 1.2%What's Next? - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
Behind the Scenes of ImmunityBio's Latest Options Trends - Benzinga
A Look At ImmunityBio (IBRX) Valuation After ASCO 2026 Spotlight And Anktiva Growth Momentum - Yahoo Finance
ImmunityBio Advances Chemotherapy Free Lymphoma Regimen As Global Anktiva Story Grows - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Trading Down 5.3%Here's Why - MarketBeat
ImmunityBio (IBRX) jumps ahead of oncology event - MSN
ImmunityBio (IBRX) Jumps Ahead of Oncology Event - Finviz
ImmunityBio Shares Gain Momentum on Strong Sales and Regulatory Progress - AD HOC NEWS
ImmunityBio's Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - openPR.com
ImmunityBio stock steadies near $7 after 15% jump; earnings next up - TechStock²
ImmunityBio, Inc. (IBRX) Investor Outlook: Analyzing the 70% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
ImmunityBio (NASDAQ:IBRX) Trading 14.5% HigherHere's What Happened - MarketBeat
ImmunityBio Surge After Saudi Approvals and FDA Meeting - Hoodline
ImmunityBio’s Stock Soars on Promising Trial Results and Strategic Advances - StocksToTrade
New Sign-Off Propels ImmunityBio - Los Angeles Business Journal
ImmunityBio rally causes $492M paper losses for short sellers - MSN
Did ImmunityBio’s (IBRX) New Chemotherapy‑Free CAR‑NK Phase 2 Trial Just Redefine Its Investment Narrative? - Sahm
Aug Ideas: Does ImmunityBio Inc have a competitive edgeOil Prices & Weekly Setup with ROI Potential - baoquankhu1.vn
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Shares Up 7.3%Still a Buy? - MarketBeat
ImmunityBio initiates another cell therapy trial with no chemotherapy needs - MSN
ImmunityBio (NASDAQ:IBRX) Trading Down 4.1%What's Next? - MarketBeat
ImmunityBio Accelerates Pipeline with New Lymphoma Trial Amid Stellar Revenue Forecast - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Stock Price Down 7.1%What's Next? - MarketBeat
Soon-Shiong, ImmunityBio Exit Challenge to Cancer Drug Financing - Bloomberg Law News
ImmunityBio extends gains after FDA views on Anktiva label expansion - MSN
ImmunityBio Stockholder Targets Soon-Shiong In Chancery - Law360
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.3%Should You Buy? - MarketBeat
Soon-Shiong Defends ImmunityBio Financing Pact for Cancer Drug - Bloomberg Law News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Bath & Body Works, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBWI - GlobeNewswire Inc.
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients - MSN
ImmunityBio Shares Maintain Upward Momentum on Clinical and Commercial Progress - AD HOC NEWS
ImmunityBio Stock Maintains Momentum with New Clinical Trial - AD HOC NEWS
ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy By Investing.com - Investing.com Nigeria
ImmunityBio (NASDAQ:IBRX) Trading Down 1.9%Should You Sell? - MarketBeat
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs - Stocktwits
Piper Sandler see label expansion potential for ImmunityBio, Inc. (IBRX)’s Anktiva following Quilt data - MSN
Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data - Yahoo Finance
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas - BioSpace
ImmunityBio Launches Phase 2 Study of Cell Therapy in Indolent Lymphomas - marketscreener.com
ImmunityBio launches phase 2 chemotherapy-free car-nk cell therapy trial with Anktiva - marketscreener.com
ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy - Investing.com
ImmunityBio Stock: Commercialization Efforts Accelerate Following Key Approvals - AD HOC NEWS
ImmunityBio shares jump after constructive FDA talks on bladder cancer therapy - MSN
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock - TechStock²
ImmunityBio (IBRX) sheds 4% on profit-taking after 14-day run - MSN
Did ANKTIVA’s Expanding Approvals and Chemo‑Free GBM Data Just Shift ImmunityBio’s (IBRX) Investment Narrative? - Sahm
Biotech Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - MSN
Clinical Promise and Regulatory Scrutiny Collide for ImmunityBio - AD HOC NEWS
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):